Marlborough’s Advanced Cell Technology, which specializes in developing regenerative eye treatments using embryonic stem cells, will conduct an early phase clinical trial with one of the leading eye institutes in the country.
ACT will work with the Wilis Eye Institute in Philadelphia, the oldest eye institute in the United States, to perform this next round of clinical trials on 12 patients. The company is testing its treatment for dry age-related macular degeneration, a condition in which cells in a patient’s eyes break down, causing blurred vision and potentially blindness. Macular degeneration impacts 25 million to 30 million people in the U.S. and Europe, ACT says.
